F M Investments LLC Invests $1.72 Million in Veeva Systems Inc. (NYSE:VEEV)

F M Investments LLC bought a new stake in Veeva Systems Inc. (NYSE:VEEV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,911 shares of the technology company’s stock, valued at approximately $1,716,000.

A number of other institutional investors have also added to or reduced their stakes in VEEV. Yousif Capital Management LLC grew its stake in Veeva Systems by 3.5% in the fourth quarter. Yousif Capital Management LLC now owns 1,777 shares of the technology company’s stock valued at $342,000 after acquiring an additional 60 shares during the period. GAMMA Investing LLC acquired a new stake in Veeva Systems in the 4th quarter valued at $158,000. Trust Co of Kansas increased its stake in Veeva Systems by 5.7% during the 4th quarter. Trust Co of Kansas now owns 24,703 shares of the technology company’s stock valued at $4,756,000 after purchasing an additional 1,325 shares in the last quarter. Linden Thomas Advisory Services LLC raised its holdings in Veeva Systems by 2.0% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 10,141 shares of the technology company’s stock worth $1,952,000 after buying an additional 201 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of Veeva Systems by 38.5% in the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 186,055 shares of the technology company’s stock valued at $38,590,000 after buying an additional 51,672 shares in the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Veeva Systems

In related news, Director Timothy S. Cabral sold 15,000 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $226.04, for a total transaction of $3,390,600.00. Following the sale, the director now owns 23,391 shares of the company’s stock, valued at approximately $5,287,301.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Timothy S. Cabral sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $226.04, for a total transaction of $3,390,600.00. Following the completion of the transaction, the director now owns 23,391 shares of the company’s stock, valued at $5,287,301.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Alan Mateo sold 3,391 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $200.86, for a total transaction of $681,116.26. Following the sale, the executive vice president now directly owns 21,983 shares in the company, valued at approximately $4,415,505.38. The disclosure for this sale can be found here. Insiders have sold 21,989 shares of company stock valued at $4,818,013 in the last 90 days. 10.98% of the stock is currently owned by company insiders.

Veeva Systems Trading Up 0.9 %

Shares of VEEV stock traded up $1.89 on Tuesday, hitting $200.95. 902,714 shares of the stock were exchanged, compared to its average volume of 981,032. Veeva Systems Inc. has a one year low of $160.21 and a one year high of $236.90. The firm’s 50 day moving average is $220.53 and its two-hundred day moving average is $202.75. The firm has a market capitalization of $32.42 billion, a PE ratio of 62.41, a P/E/G ratio of 2.00 and a beta of 0.74.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Thursday, February 29th. The technology company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. The firm had revenue of $630.62 million during the quarter, compared to analyst estimates of $620.75 million. On average, sell-side analysts expect that Veeva Systems Inc. will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on VEEV shares. UBS Group boosted their target price on shares of Veeva Systems from $185.00 to $235.00 and gave the stock a “neutral” rating in a research report on Monday, February 26th. Oppenheimer restated an “outperform” rating and issued a $225.00 target price on shares of Veeva Systems in a report on Thursday, February 22nd. Piper Sandler upped their price target on Veeva Systems from $220.00 to $245.00 and gave the stock an “overweight” rating in a report on Friday, March 1st. Raymond James reissued an “outperform” rating and issued a $260.00 price target on shares of Veeva Systems in a research report on Tuesday, March 26th. Finally, Citigroup lifted their price objective on shares of Veeva Systems from $240.00 to $264.00 and gave the stock a “buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $234.90.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.